Novartis' Afinitor extends progression-free survival in neuroendocrine tumors

Swiss drug major Novartis (NOVN: VX) announced that the Phase III study of Afinitor (everolimus) tablets plus best supportive care in nonfunctional neuroendocrine tumors of gastrointesinal or lung origin met its primary endpoint.

It showed that Afinitor significantly extended progression-free survival compared to placebo plus best supportive care in neuroendocrine tumors, a rare type of cancer originating in neuroendocrine cells found throughout the body. They are most often found in the gastrointestinal tract, lungs or pancreas.

Alessandro Riva, global head of Novartis oncology development and medical affairs, said: "We look forward to presenting the findings from the RADIANT-4 trial of everolimus, which has the potential to become an important treatment option for patients with advanced nonfunctional GI or lung NET. The results will serve as the basis of planned worldwide regulatory filings for everolimus in these two types of NET, bringing us closer to our goal of offering Afinitor for these patients."